Response to: improvements to out-of-hospital cardiac arrest and opioid overdose treatment algorithms to enhance positive outcomes

Conflict of interest statement

Authors CL and PS are employees of Indivior Inc. AD consults for Zmi Pharma (Carlsbad, CA) and received grants from the FDA regarding work related to nalmefene.

Author contributions

All authors wrote the manuscript and approved the final version.

Funding

None.

Ethics approval of studies and informed consent

Not applicable.

Acknowledgments

None.

References

[1] Davis CR, Schinella M, Papish M. Improvements to out-of-hospital cardiac arrest and opioid overdose treatment algorithms to enhance positive outcomes. Emerg Crit Care Med. 2025; 5(2):61-64. doi:10.1097/EC9.0000000000000141

[2] Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012; 367(2):146-155

[3] Friedman MS, Manini AF. Validation of criteria to guide prehospital naloxone administration for drug-related altered mental status. J Med Toxicol. 2016; 12(3):270-275. doi:10.1007/s13181-016-0549-5

[4] Cano M, Daniulaityte R, Marsiglia F. Xylazine in overdose deaths and forensic drug reports in US states, 2019-2022. JAMA Netw Open. 2024; 7(1):e2350630. doi:10.1001/jamanetworkopen.2023.50630

[5] Choi S, Irwin MR, Kiyatkin EA. Xylazine effects on opioid-induced brain hypoxia. Psychopharmacology (Berl). 2023; 240(7):1561-1571. doi:10.1007/s00213-023-06390-y

[6] Lowry JA, Brown JT. Significance of the imidazoline receptors in toxicology. Clin Toxicol (Phila). 2014; 52(5):454-469. doi:10.3109/15563650.2014.898770

[7] Cano M, Timmons P, Hooten M, Sweeney K. Drug supply measures and drug overdose mortality in the era of fentanyl and stimulants. Drug Alcohol Depend Rep. 2023; 9:100197. doi:10.1016/j.dadr.2023.100197

[8] Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional Drug Overdose Death Counts. Hyattsville, MD: National Center for Health Statistics; 2025. Accessed July 30, 2025. https://dx.doi.org/10.15620/cdc/20250305009.

[9] Sutter ME, Gerona RR, Davis MT, et al. Fatal fentanyl: one pill can kill. Acad Emerg Med. 2017; 24(1):106-113. doi:10.1111/acem.13034

[10] Strauss DG, Li Z, Chaturbedi A, et al. Intranasal naloxone repeat dosing strategies and fentanyl overdose: a simulation-based randomized clinical trial. JAMA Netw Open. 2024; 7(1):e2351839. doi:10.1001/jamanetworkopen.2023.51839

[11] van Lemmen MA, van Velzen M, Sarton EY, Dahan A, Niesters M, van der Schrier RM. A comparison of intramuscular (Zimhi) and intranasal naloxone (Narcan) in reversal of fentanyl-induced apnea: a randomized, crossover, open-label trial. Nat Commun. 2025; 16(1):4659. doi:10.1038/s41467-025-59932-7

[12] Curay CM, Irwin MR, Kiyatkin EA. The pattern of brain oxygen response induced by intravenous fentanyl limits the time window of therapeutic efficacy of naloxone. Neuropharmacology. 2023; 231:109507. doi:10.1016/j.neuropharm.2023.109507

[13] Mann J, Samieegohar M, Chaturbedi A, et al. Development of a translational model to assess the impact of opioid overdose and naloxone dosing on respiratory depression and cardiac arrest. Clin Pharmacol Ther. 2022; 112(5):1020-1032. doi:10.1002/cpt.2696

[14] Laffont CM, Purohit P, Delcamp N, Gonzalez-Garcia I, Skolnick P. Comparison of intranasal naloxone and intranasal nalmefene in a translational model assessing the impact of synthetic opioid overdose on respiratory depression and cardiac arrest. Front Psych. 2024; 15:1399803. doi:10.3389/fpsyt.2024.1399803

[15] Cassel JA, Daubert JD, DeHaven RN. [(3)H]Alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists. Eur J Pharmacol. 2005; 520(1-3):29-36. doi:10.1016/j.ejphar.2005.08.008

[16] Crystal R, Ellison M, Purdon C, Skolnick P. Pharmacokinetic properties of an FDA-approved intranasal nalmefene formulation for the treatment of opioid overdose. Clin Pharmacol Drug Dev. 2024; 13(1):58-69. doi:10.1002/cpdd.1312

[17] Ellison M, Hutton E, Webster L, Skolnick P. Reversal of opioid-induced respiratory depression in healthy volunteers: comparison of intranasal nalmefene and intranasal naloxone. J Clin Pharmacol. 2024; 64(7):828-839. doi:10.1002/jcph.2421